System genetic analysis of intestinal cancer and periodontitis development as influenced by aging and diabesity using Collaborative Cross mice

Abstract

It is increasingly recognized that young, chow-fed inbred mice poorly model the complexity of human carcinogenesis. In humans, age and adiposity are major risk factors for malignancies, but most genetically engineered mouse models (GEMM) induce carcinogenesis too rapidly to study these influences. Standard strains, such as C57BL/6, commonly used in GEMMs, further limit the exploration of aging and metabolic health effects. A similar challenge arises in modeling periodontitis, a disease influenced by aging, diabesity, and genetic architecture. We propose using diverse mouse populations with hybrid vigor, such as the Collaborative Cross (CC) ×  Apc^Min hybrid, to slow disease progression and better model human colorectal cancer (CRC) and comorbidities. This perspective highlights the advantages of this model, where delayed carcinogenesis reveals interactions with aging and adiposity. Unlike Apc^Min mice, which develop cancer rapidly, CC ×  Apc^Min hybrids recapitulate human-like progression. This facilitates the identification of modifier loci affecting inflammation, diet susceptibility, organ size, and polyposis distribution. The CC ×  Apc^Min model offers a transformative platform for studying CRC as a disease of adulthood, reflecting its complex interplay with aging and comorbidities. The insights gained from this approach will enhance early detection, management, and treatment strategies for CRC and related conditions.

Keywords

Aging and intestinal cancer / gene identification of aging and cancer / gene maping / type 2 diabetes and intestinal cancer

References

[1] Zanke BW, Greenwood CMT, Rangrej J, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat Genet. 2007; 39(8): 989-994.

[2] Dorman A, Binenbaum I, Abu-Toamih Atamni HJ, et al. Genetic mapping of novel modifiers for Apc Min induced intestinal polyps' development using the genetic architecture power of the collaborative cross mice. BMC Genomics. 2021; 22(1): 566.

[3] Fostira F, Thodi G, Sandaltzopoulos R, Fountzilas G, Yannoukakos D. Mutational spectrum of APC and genotype-phenotype correlations in Greek FAP patients. BMC Cancer. 2010; 10: 10.

[4] Sheng JQ, Cui WJ, Fu L, et al. APC gene mutations in Chinese familial adenomatous polyposis patients. World J Gastroenterol. 2010; 16(12): 1522-1526.

[5] Silverman KA, Koratkar R, Siracusa LD, Buchberg AM. Identification of the modifier of Min 2 (Mom2) locus, a new mutation that influences Apc-induced intestinal neoplasia. Genome Res. 2002; 12(1): 88-97.

[6] Dorman A, Baer D, Tomlinson I, Mott R, Iraqi FA. Genetic analysis of intestinal polyp development in collaborative cross mice carrying the Apc Min/+ mutation. BMC Genet. 2016; 17(1): 1-11.

[7] Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007; 447(7148): 1087-1093.

[8] Barrett J, Jiwa M, Rose P, Hamilton W. Pathways to the diagnosis of colorectal cancer: an observational study in three UK cities. Fam Pract. 2006; 23(1): 15-19.

[9] Van Der Auwera I, Van Laere SJ, Van Den Bosch SM, et al. Aberrant methylation of the adenomatous polyposis coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype. Br J Cancer. 2008; 99(10): 1735-1742.

[10] Moser AR, Mattes EM, Dove WF, Lindstrom MJ, Haag JD, Gould MN. APC(Min), a mutation in the murine APC gene, predisposes to mammary carcinomas and focal alveolar hyperplasias. Proc Natl Acad Sci USA. 1993; 90(19): 8977-8981.

[11] Chen SP, Tsai ST, Jao SW, et al. Single nucleotide polymorphisms of the APC gene and colorectal cancer risk: a case-control study in Taiwan. BMC Cancer. 2006; 6: 6.

[12] Cormier RT, Dove WF. Dnmt1N/+ reduces the net growth rate and multiplicity of intestinal adenomas in C57BL/6-multiple intestinal neoplasia (Min)/+ mice independently of p53 but demonstrates strong synergy with the modifier of Min 1AKR resistance allele. Cancer Res. 2000; 60(14): 3965-3970.

[13] Cormier RT, Hong KH, Halberg RB, et al. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat Genet. 1997; 17(1): 88-91.

[14] Jackstadt R, Sansom OJ. Mouse models of intestinal cancer. J Pathol. 2016; 238(2): 141-151.

[15] Septer S, Zhang L, Lawson CE, Cocjin J, Attard T, Ardinger HH. Aggressive juvenile polyposis in children with chromosome 10q23 deletion. World J Gastroenterol: WJG. 2013; 19(14): 2286-2292.

[16] Sameer AS. Colorectal cancer: molecular mutations and polymorphisms. Front Oncologia. 2013; 3: 38942.

[17] Hisamuddin IM, Yang VW. Molecular genetics of colorectal cancer: an overview. Curr Colorectal Cancer Rep. 2006; 2(2): 53-59.

[18] Seo JY, Jin EH, Chung GE, et al. The risk of colorectal cancer according to obesity status at four-year intervals: a nationwide population-based cohort study. Sci Rep. 2023; 13(1): 1-9.

[19] Cormier RT, Bilger A, Lillich AJ, et al. The Mom1AKR intestinal tumor resistance region consists of Pla2g2a and a locus distal to D4Mit64. Oncogene. 2000; 19(28): 3182-3192.

[20] Jacob JB, Wei KC, Bepler G, et al. Identification of actionable targets for breast cancer intervention using a diversity outbred mouse model. iScience. 2023; 26(4): 106320.

[21] Simon G, Plouhinec JL, Gilardi-Hebenstreit P, Sorre B, Collignon J. BMP signaling modulations control primitive streak patterning. bioRxiv. 2024; 1-43.

[22] Wilkening S, Chen B, Bermejo JL, Canzian F. Is there still a need for candidate gene approaches in the era of genome-wide association studies? Genomics. 2009; 93(5): 415-419.

[23] Nam K, Kim J, Lee S. Genome-wide study on 72,298 individuals in Korean biobank data for 76 traits. Cell Genomics. 2022; 2(10): 1-11.

[24] Innocenti F, Sibley AB, Patil SA, et al. Genomic analysis of germline variation associated with survival of patients with colorectal cancer treated with chemotherapy plus biologics in CALGB/SWOG 80405 (alliance). Clin Cancer Res. 2021; 27(1): 267-275.

[25] Garcia-Etxebarria K, Etxart A, Barrero M, et al. Performance of the use of genetic information to assess the risk of colorectal cancer in the Basque population. Cancers (Basel). 2022; 14(17): 4193.

[26] Pander J, Van Huis-Tanja L, Böhringer S, et al. Genome wide association study for predictors of progression free survival in patients on capecitabine, oxaliplatin, bevacizumab and cetuximab in first-line therapy of metastatic colorectal cancer. PLoS One. 2015; 10(7): e0131091.

[27] Park HA, Edelmann D, Canzian F, et al. Predictive polygenic score for outcome after first-line oxaliplatin-based chemotherapy in colorectal cancer patients using supervised principal component analysis. Cancer Epidemiol Biomarkers Prev. 2022; 31(11): 2087-2091.

[28] Tanikawa C, Kamatani Y, Takahashi A, et al. GWAS identifies two novel colorectal cancer loci at 16q24.1 and 20q13.12. Carcinogenesis. 2018; 39(5): 652-660.

[29] McCartney DL, Min JL, Richmond RC, et al. Genome-wide association studies identify 137 genetic loci for DNA methylation biomarkers of aging. Genome Biol. 2021; 22(1): 194.

[30] Luo A, Jung J, Longley M, et al. Epigenetic aging is accelerated in alcohol use disorder and regulated by genetic variation in APOL2. Neuropsychopharmacology. 2020; 45(2): 327-336.

[31] Lin WY. Genome-wide association study for four measures of epigenetic age acceleration and two epigenetic surrogate markers using DNA methylation data from Taiwan biobank. Hum Mol Genet. 2022; 31(11): 1860-1870.

[32] Munz M, Willenborg C, Richter GM, et al. A genome-wide association study identifies nucleotide variants at SIGLEC5 and DEFA1A3 as risk loci for periodontitis. Hum Mol Genet. 2017; 26(13): 2577-2588.

[33] Freitag-Wolf S, Dommisch H, Graetz C, et al. Genome-wide exploration identifies sex-specific genetic effects of alleles upstream NPY to increase the risk of severe periodontitis in men. J Clin Periodontol. 2014; 41(12): 1115-1121.

[34] Freitag-Wolf S, Munz M, Wiehe R, et al. Smoking modifies the genetic risk for early-onset periodontitis. J Dent Res. 2019; 98(12): 1332-1339.

[35] Freitag-Wolf S, Munz M, Junge O, et al. Sex-specific genetic factors affect the risk of early-onset periodontitis in Europeans. J Clin Periodontol. 2021; 48(11): 1404-1413.

[36] Jiang K, Sun Y, Wang C, et al. Genome-wide association study identifies two new susceptibility loci for colorectal cancer at 5q23.3 and 17q12 in Han Chinese. Oncotarget. 2015; 6(37): 40327-40336.

[37] Tomczak K, Czerwińska P, Wiznerowicz M. The cancer genome atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015; 19(1A): A68-A77.

[38] Ioannidis JPA. Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ. 2009; 181(8): 488-493.

[39] Dietrich WF, Lander ES, Smith JS, et al. Genetic identification of mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell. 1993; 75(4): 631-639.

[40] Kwong LN, Shedlovsky A, Biehl BS, Clipson L, Pasch CA, Dove WF. Identification of Mom7, a novel modifier of ApcMin/1 on mouse chromosome 18. Genetics. 2007; 176(2): 1237-1244.

[41] Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/β-catenin/Tcf pathway in colorectal cancer. Cancer Res. 1998; 58(6): 1130-1134.

[42] Silverman KA, Koratkar R, Siracusa LD, Buchberg AM. Exclusion of Madh2, Madh4, and Madh7 as candidates for the modifier of Min 2 (Mom2) locus. Mamm Genome. 2003; 14(2): 119-129.

[43] Huang EH, Park JC, Appelman H, et al. Induction of inflammatory bowel disease accelerates adenoma formation in Min +/− mice. Surgery. 2006; 139(6): 782-788.

[44] Muluke M, Gold T, Kiefhaber K, et al. Diet-induced obesity and its differential impact on periodontal bone loss. J Dent Res. 2016; 95(2): 223-229.

[45] Harada N, Tamai Y, Ishikawa TO, et al. Intestinal polyposis in mice with a dominant stable mutation of the β-catenin gene. EMBO J. 1999; 18(21): 5931-5942.

[46] Blasco-Baque V, Garidou L, Pomié C, et al. Periodontitis induced by Porphyromonas gingivalis drives periodontal microbiota dysbiosis and insulin resistance via an impaired adaptive immune response. Gut. 2016; 66(5): 872-885.

[47] Hajishengallis G, Darveau RP, Curtis MA. The keystone-pathogen hypothesis. Nat Rev Microbiol. 2012; 10: 10-725.

[48] Branchereau M, Reichardt F, Loubieres P, et al. Periodontal dysbiosis linked to periodontitis is associated with cardiometabolic adaptation to high-fat diet in mice. Am J Physiol Gastrointest Liver Physiol. 2016; 310(11): G1091-G1101.

[49] Churchill GA, Airey DC, Allayee H, et al. The collaborative cross, a community resource for the genetic analysis of complex traits. Nat Genet. 2004; 36(11): 1133-1137.

[50] Iraqi FA, Churchill G, Mott R. The collaborative cross, developing a resource for mammalian systems genetics: a status report of the Wellcome Trust cohort. Mamm Genome. 2008; 19(6): 379-381.

[51] Iraqi FA, Mahajne M, Salaymah Y, et al. The genome architecture of the collaborative cross mouse genetic reference population. Genetics. 2012; 190(2): 389-401.

[52] Aylor DL, Valdar W, Foulds-Mathes W, et al. Genetic analysis of complex traits in the emerging collaborative cross. Genome Res. 2011; 21(8): 1213-1222.

[53] Mathes WF, Aylor DL, Miller DR, et al. Architecture of energy balance traits in emerging lines of the collaborative cross. Am J Physiol Endocrinol Metab. 2011; 300(6): E1124-E1134.

[54] Shusterman A, Munz M, Richter G, et al. The PF4/PPBP/CXCL5 gene cluster is associated with periodontitis. J Dent Res. 2017; 96(8): 945-952.

[55] Abu-Toamih Atamni HJ, Kontogianni G, Binenbaum I, et al. Hepatic gene expression variations in response to high-fat diet-induced impaired glucose tolerance using RNAseq analysis in collaborative cross mouse population. Mamm Genome. 2019; 30: 9-10.

[56] Lone IM, Iraqi FA. Genetics of murine type 2 diabetes and comorbidities. Mamm Genome. 2022; 33(3): 421-436.

[57] Abu-Toamih-Atami HJ, Lone IM, Binenbaum I, Midlej K, Mott R, Iraqi FA. Mapping QTL underlying body weight changes that act at different times during high-fat diet challenge in collaborative cross mice. Published Online. 2024.

[58] Keane TM, Goodstadt L, Danecek P, et al. Mouse genomic variation and its effect on phenotypes and gene regulation. Nature. 2011; 477(7364): 289-294.

[59] Lone IM, Zohud O, Midlej K, Proff P, Watted N, Iraqi FA. Skeletal class II malocclusion: from clinical treatment strategies to the roadmap in identifying the genetic bases of development in humans with the support of the collaborative cross mouse population. J Clin Med. 2023; 12(15): 5148.

[60] Beck JA, Lloyd S, Hafezparast M, et al. Genealogies of mouse inbred strains. Nat Genet. 2000; 24(1): 23-25.

[61] Roberts A, Pardo-Manuel De Villena F, Wang W, McMillan L, Threadgill DW. The polymorphism architecture of mouse genetic resources elucidated using genome-wide resequencing data: implications for QTL discovery and systems genetics. Mamm Genome. 2007; 18: 6-7.

[62] Durrant C, Tayem H, Yalcin B, et al. Collaborative cross mice and their power to map host susceptibility to aspergillus fumigatus infection. Genome Res. 2011; 21(8): 1239-1248.

[63] Yosief RHS, Lone IM, Nachshon A, Himmelbauer H, Gat-Viks I, Iraqi FA. Identifying genetic susceptibility to aspergillus fumigatus infection using collaborative cross mice and RNA-seq approach. Animal Model Exp Med. 2024; 7(1): 36-47.

[64] Zohud O, Lone IM, Midlej K, et al. Towards genetic dissection of skeletal class III malocclusion: a review of genetic variations underlying the phenotype in humans and future directions. J Clin Med. 2023; 12(9): 3212.

[65] Yehia R, Lone IM, Yehia I, Iraqi FA. Studying the Pharmagenomic effect of Portulaca oleracea extract on anti-diabetic therapy using the collaborative cross mice. Phytomedicine Plus. 2023; 3(1): 100394.

[66] Lone IM, Zohud O, Nashef A, et al. Dissecting the complexity of skeletal-malocclusion-associated phenotypes: mouse for the rescue. Int J Mol Sci. 2023; 24(3): 2570.

[67] Yang H, Wang X, Wang P, et al. Thirdhand tobacco smoke exposure increases the genetic background-dependent risk of pan-tumor development in collaborative cross mice. Environ Int. 2023; 174: 107876.

[68] Wang P, Wang Y, Langley SA, et al. Diverse tumour susceptibility in collaborative cross mice: identification of a new mouse model for human gastric tumourigenesis. Gut. 2019; 68(11): 1942-1952.

[69] Zohud O, Midlej K, Lone IM, Nashef A, Abu-Elnaaj I, Iraqi FA. Studying the effect of the host genetic background of juvenile polyposis development using collaborative cross and Smad4 Knock-out mouse models. Int J Mol Sci. 2024; 25(11): 5812.

[70] Ghnaim A, Lone IM, Ben NN, Iraqi FA. Unraveling the host genetic background effect on internal organ weight influenced by obesity and diabetes using collaborative cross mice. Int J Mol Sci. 2023; 24(9): 1-18.

[71] Nashef A, Qabaja R, Hazan R, et al. The collaborative cross-mouse population for studying genetic determinants underlying alveolar bone loss due to polymicrobial synergy and dysbiosis. Int J Mol Sci. 2023; 25(1): 473.

[72] Zohud O, Lone IM, Nashef A, Iraqi FA, Fuad Iraqi CA. Towards system genetics analysis of head and neck squamous cell carcinoma using the mouse model, cellular platform, and clinical human data. Anim Models Exp Med. 2023; 6: 537-558.

[73] Ansorge WJ. Next-generation DNA sequencing techniques. New Biotechnol. 2009; 25: 4-203.

[74] Voelkerding KV, Dames SA, Durtschi JD. Next-generation sequencing: from basic research to diagnostics. Published Online. 2009; 55: 641-658.

[75] Ng SB, Buckingham KJ, Lee C, et al. Exome sequencing identifies the cause of a mendelian disorder. Nat Genet. 2010; 42(1): 30-35.

[76] Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010; 31(1): 27-36.

[77] Syeda F, Fagan RL, Wean M, et al. The replication focus targeting sequence (RFTS) domain is a DNA-competitive inhibitor of Dnmt1. J Biol Chem. 2011; 286(17): 15344-15351.

[78] Huang J, Stewart A, Maity B, et al. RGS6 suppresses Ras-induced cellular transformation by facilitating Tip60-mediated Dnmt1 degradation and promoting apoptosis. Oncogene. 2014; 33(27): 3604-3611.

[79] Wu BK, Mei SC, Brenner C. RFTS-deleted DNMT1 enhances tumorigenicity with focal hypermethylation and global hypomethylation. Cell Cycle. 2014; 13(20): 3222-3231.

[80] Wu BK, Brenner C. Suppression of TET1-dependent DNA demethylation is essential for KRAS-mediated transformation. Cell Rep. 2014; 9(5): 1827-1840.

[81] Yu X, Zhao H, Wang R, et al. Cancer epigenetics: from laboratory studies and clinical trials to precision medicine. Cell Death Dis. 2024; 10(1): 1-12.

[82] Ilango S, Paital B, Jayachandran P, Padma PR, Nirmaladevi R. Epigenetic alterations in cancer. Front Biosci. 2020; 25(6): 1058-1109.

[83] Villeneuve LM, Reddy MA, Natarajan R. Epigenetics: deciphering its role in diabetes and its chronic complications. Clin Exp Pharmacol Physiol. 2011; 38(7): 451-459.

[84] Kowluru RA, Mohammad G. Epigenetic modifications in diabetes. Metabolism. 2022; 126: 126.

[85] Zhang H, Pollin TI. Epigenetics variation and pathogenesis in diabetes. Curr Diab Rep. 2018; 18(11): 1-11.

[86] Khouly I, Braun RS, Ordway M, et al. The role of DNA methylation and histone modification in periodontal disease: a systematic review. Int J Mol Sci. 2020; 21(17): 1-37.

[87] Ari G, Cherukuri S, Namasivayam A. Epigenetics and periodontitis: a contemporary review. J Clin Diagn Res. 2016; 10(11): ZE07-ZE09.

[88] Larsson L, Castilho RM, Giannobile WV. Epigenetics and its role in periodontal diseases: a state-of-the-art review. J Periodontol. 2015; 86(4): 556-568.

[89] Larsson L. Current concepts of epigenetics and its role in periodontitis. Curr Oral. Health Rep. 2017; 4(4): 286-293.

[90] Gomez RS, Dutra WO, Moreira PR. Epigenetics and periodontal disease: future perspectives. Inflamm Res. 2009; 58(10): 625-629.

[91] Zabransky DJ, Jaffee EM, Weeraratna AT. Shared genetic and epigenetic changes link aging and cancer. Trends Cell Biol. 2022; 32(4): 338-350.

[92] Saul D, Kosinsky RL. Molecular sciences epigenetics of aging and aging-associated diseases. Int J Mol Sci. 2021; 22: 1-25.

[93] Soller M, Abu-Toamih Atamni HJ, Binenbaum I, Chatziioannou A, Iraqi FA. Designing a QTL mapping study for implementation in the realized collaborative cross genetic reference population. Curr Protoc Mouse Biol. 2019; 9(4): e66.

[94] Keele GR, Crouse WL, Kelada SNP, Valdar W. Determinants of QTL mapping power in the realized collaborative cross. G3 (Bethesda). 2019; 9(5): 1707-1727.

[95] Shusterman A, Salyma Y, Nashef A, et al. Genotype is an important determinant factor of host susceptibility to periodontitis in the collaborative cross and inbred mouse populations. BMC Genet. 2013; 14(1): 1-11.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.